Evolution of antiviral treatment chronic for hepatitis B, C and D
https://doi.org/10.22625/2072-6732-2009-1-4-23-35
Abstract
In the review is presented evolution of sights on treatment of patients with chronic hepatitises since 70-th years of XX century to the present days. Stages of development of therapy sick of chronic hepatitises В, С and D are consistently characterised. The basic emphasis is made on a
current state of a problem and the prospects opening before researchers. Algorithms of treatment of patients with chronic
hepatitises are presented.
About the Authors
K. V. Zhdanov
Military-Medical Academy of S.M.Kirov, Saint-Petersburg
Russian Federation
Russian Federation
K. V. Kozlov
Military-Medical Academy of S.M.Kirov, Saint-Petersburg
Russian Federation
Russian Federation
V. S. Sukachev
Military-Medical Academy of S.M.Kirov, Saint-Petersburg
Russian Federation
Russian Federation
References
1. Sherlock S. Course of long incubation (virus B) hepatitis / S. Sherlock // Brit. Med. Bull. 1972. – Vol.28. –P. 109–113.
2. Levene C. Incidence of antibodies against betalipoproteins (Ag system), and the factors influencing isoimmunisation in transfused patients in the U.S.A. and Italy / C. Levene, B.S. Blumberg, A. Vierrucci et al. // Lancet. – 1967. – Vol.2, №7516. – P. 582–585.
3. Dane D.S. Virus-like particles in serum of patients with Australia-antigen-associated hepatitis / D.S. Dane, C.H. Cameron, M. Briggs // Lancet. – 1970. – Vol.1, №7649. – P. 695–698.
4. Vilela M.D. Action of an anti-viral on the Australia antigen in patients with hepatitis A virus and in healthy carriers /M.D. Vilela, W.A. Siqueira, L.D. Rodriguez et al. // G E N. – 1977. – Vol. 31, №3. –P. 149–155.
5. Whitley R. Vidarabine: a preliminary review of its pharmacological properties and therapeutic use / R. Whitley, C. Alford, F. Hess et al. // Drugs. – 1980. – Vol. 20, №4. – P. 267–282.
6. Auer I.O. Therapy of chronic hepatitis (author’s transl) / I.O. Auer // Leber Magen Darm. – 1980. – Vol.10, №5. – P. 251–258.
7. Sherlock S. Treatment of chronic hepatitis /S. Sherlock // Ann Acad Med Singapore. – 1980 – Vol.9, №2. – P. 185–187.
8. Hafkin B. Effects of interferon and adenine arabinoside treatment of hepatitis B virus infection on cellular immune responses / B. Hafkin, R.B. Pollard, M.L. Tiku et al. // Antimicrob Agents Chemother – 1979. – Vol.16, №6. – P. 781–787.
9. Fattovich G. Long-term effect of low dose recombinant interferon therapy in patients with chronic hepatitis B /G. Fattovich, L. Brollo, S. Boscarro et al. // J.Hepatol. – 1989. – Vol.9, №3. – P. 331–337.
10. Coppens J.P. Prospective trial of recombinant leucocyte interferon in chronic hepatitis B: a 10-month follow up study / J.P. Coppens, C. Cornu, E. Lens et al. // Liver. – 1989. – Vol.9, №5. – P. 307–313.
11. Porres J.C. Different doses of recombinant alpha interferon in the treatment of chronic hepatitis B patients without antibodies against the human immunodeficiency virus / J.C. Porres, V. Carreo, I. Mora et al. // Hepatogastroenterology. – 1988. – Vol.35, №6. – P. 300–303.
12. Brook M.G. Histological improvement after anti-viral treatment for chronic hepatitis B virus infection / M.G. Brook, L. Petrovic, J.A. McDonald et al. // J. Hepatol. – 1989. – Vol.8, №2. – P. 218–225.
13. Marcellin P. Vidarabine treatment of chronic active hepatitis associated with hepatitis B virus multiplication. A randomized multicenter study / P. Marcellin, D. Ouzan, F. Degos et al. // Gastroenterol Clin. Biol. – 1987. – Vol.11, №8-9. – P. 568–573.
14. Di Bisciglie A.M. A randomized, controlled trial of recombinant alpha-interferon therapy for chronic hepatitis B /A.M. Di Bisciglie, T.L. Fong, M.W. Fried et al. // Am J Gastroenterol. – 1993. – Vol.88, №11. – P. 1887–1892.
15. Interferon treatment in patients with chronic hepatitis B: a meta-analysis of the published literature. / F. Tin, A. Liberati, A. Crax et al. // J Hepatol. 1993 Jun;18(2):154–62.
16. Lok A.S. Treatment of chronic hepatitis B / A.S. Lok //J. Viral. Hepat. – 1994. – Vol.1, №2. – P. 105–124.
17. Dusheiko G.M. Lamivudine treatment of chronic hepatitis B / G.M. Dusheiko // Rev. Med. Virol. – 1998. –Vol.8 – P. 153–159.
18. Hong J.H. Current status of anti-HBV chemotherapy /J.H. Hong, Y. Choi, B.K. Chun et al. // Arch Pharm. Res. –1998. – Vol.21, №2. – P. 89–105.
19. Doong S.L. Inhibition of the replication of hepatitis B virus in vitro by 2’,3’-dideoxy-3’-thiacytidine and related analogues / S.L. Doong, C.H. Tsai, R.F. Schinazi et al. // Proc. Natl. Acad. Sci. U S A. – 1991. – Vol.88, №19. – P. 8495–8499.
20. Lai C.L. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group / C.L. Lai, R.N. Chien, N.W. Leung et al. // N. Engl. J. Med. – 1998. – Vol.339. – P. 61–68.
21. Sokal E. Doze finding and safety of lamivudine in children and adolescents with chronic hepatitis B / E. Sokal, E.A. Roberts, G. Mieli-Vergani et al. // Hepatology. – 1998. – Vol.28. – P. 489A.
22. Grellier L. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis / L. Grellier,D. Mutimer, M. Ahmend et al. // Lancet. - 1996. – Vol.348. – P. 1212–1215.
23. Perrilo R. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation / R. Perrilo, J. Rakela, J. Deinstage et al. // Hepatology. – 1999. – Vol.29. – P. 1581–1586.
24. Hadziyannis S.J. Adefovir Dipivoxil 438 Study Group. Long-term therapy with adefovir dipivoxil for HBeAgnegative chronic hepatitis B for up to 5 years / S.J. Hadziyannis, N.C. Tassopoulos, E.J. Heathcote et al. // Gastroenterology. – 2006. – Vol.131, №6. – P. 1743–1751.
25. Melegari M. Hepatitis B mutants associated with 3 TC and famciclovir administration are replication defective /M. Melegari, P.P. Scaglioni, J.R. Wands // Hepalology. – 1998. – Vol.27. – P. 628–633.
26. Hadziyannis S.J. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B / S.J. Hadziyannis, G.V. Papatheodoridis, E. Dimou et al. // Hepatology. – 2000. – Vol.32, №4, Pt.1. – P. 847–851.
27. Lin S.M. Interferon therapyin HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma / S.M. Lin, M.L. Yu, C.M. Lee et al. // J. Hepatol. – 2007. – Vol.46, №1. – P. 45–52.
28. Lampertico P. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy / P. Lampertico, E. Del Ninno, M. Vigan et al. // Hepatology. – 2003. – Vol.37, №4. – P. 756–763.
29. Moucari R. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up / R. Moucari, A. Korevaar, O. Lada et al. // J. Hepatol. – 2009. – Vol.50, №6. – P. 1084– 1092.
30. Fattovich G. Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis (EUROHEP) / G. Fattovich, G. Giustina, J. Sanchez- Tapias et al. // Am J. Gastroenterol. – 1998. – Vol.93, №6. – P. 896–900.
31. Lau G.K. Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B / G.K. Lau, T. Piratvisuth, K.X. Luo et al. // N. Engl. J. Med. – 2005. – Vol.352, №26. – P. 2682–2695.
32. Janssen H.L. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial / H.L. Janssen, M. van Zonneveld, H. Senturk et al. // Lancet. – 2005. – Vol.365, №9454. – P. 123–129.
33. Chan H.L. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone / H.L. Chan, N.W. Leung, A.Y. Hui et al. // Ann Intern Med. – 2005. – Vol.142, №4. – P. 240–250.
34. Marcellin P. Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B / P. Marcellin, G.K. Lau, F. Bonino et al. // N. Engl. J. Med. – 2004. – Sep.
35. Buster E.H. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b / E.H. Buster, H.J. Flink, Y. Cakaloglu et al. // Gastroenterology. – 2008. – Vol.135, №2. – P. 459–467.
36. Marcellin P. Peginterferon alfa-2a in HBeAg-negative Chronic Hepatitis B Study Group. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a / P. Marcellin, F. Bonino, G.K. Lau et al. // Gastroenterology. – 2009. – Vol.136, №7. – P. 2169– 2179. – e.1–4.
37. Buster E.H. Factors that Predict Response of Patients with Hepatitis Be Antigen-Positive Chronic Hepatitis B to Peginterferon-alpha / E.H. Buster, B.E. Hansen, G.K. Lau et al. // Gastroenterology. – 2009. – Sep. 5. В печати.
38. Нурмухаметова Е.А. Генотипы вируса гепатита В: потенциальное клиническое значение / Е.А. Нурмухаметова, Н.П. Блохина // Фарматека. – 2008. – Т.156, №2. – С.33–35.
39. EASL Clinical Practice Guidelines: managment of chronic hepatitis B. European Association For The Study Of The Liver // J. Hepatol. – 2009. – Vol. 50, №2. – P. 227–242.
40. Brunetto M.R. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAgnegative chronic hepatitis B / M.R. Brunetto, F. Moriconi, F. Bonino et al. // J. Gepatol. – 2009. – Vol.49, №4. – P. 1141–1150.
41. Moucari R. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa- 2a in HBeAg-negative patients / R. Moucari, V. Mackiewicz, O. Lada et al. // Hepatology. – 2009. – Vol.49, №4. – P. 1151–1157. PEGASYS and its association with post-treatment response in HBeAg positive chronic hepatitis B.
42. GKK Lau // Presented at: Asian Pacific Association for the Study of the Liver (APASL). –Poster 083. – February 13–16, 2009; Hong Kong, China.
43. Moucari R. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up / R. Moucari, A. Korevaar, O. Lada et al. // J. Hepatol. – 2009. – Vol.50, №6. – P. 1084– 1092.
44. Chang T.T. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B; BEHoLD
45. AI463022 Study Group / T.T. Chang, R.G. Gish, R. de Man et al. // N. Engl. J. Med. – 2006. – Vol.354, №10. – P. 1001– 1010.
46. Lai C.L. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B; BEHoLD AI463027 Study Group / C.L. Lai, D. Shouval, A.S. Lok et al. // N. Engl. J. Med. – 2006. – Vol. 354, №10. – P. 1011–1020.
47. Gish R.G. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B / R.G. Gish //Gastroenterology. – 2007. – Vol.133. – P. 1437–1444.
48. Lai C.L. Telbivudine versus lamivudine in patients with chronic hepatitis B / C.L. Lai, E. Gane, Y.F. Liaw et al. // N. Engl. J. Med. – 2007. – Vol.357. – P. 2576–88.
49. Liaw Y.F. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B; GLOBE Study Group / Y.F. Liaw, E. Gane, N. Leung et al. // J. Gastroenterol. – 2009. – Vol.136, №2. – P. 486–495.
50. Zeuzem S. Baseline characteristics and early ontreatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B / S. Zeuzem, E. Gane, Y.F. Liaw et al. // J. Hepatol. – 2009. – Vol.51, №1. – P. 11–20.
51. Keeffe E.B. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update / E.B. Keeffe, D.T. Dieterich, S.H. Han et al. // Clin. Gastroenterol. Hepatol. – 2008. – Vol.6, №12. – P. 1315– 1341.
52. Marcellin P. Tenofovir dixoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B / P. Marcellin, E.J. Heathcote, M. Buti et al. // N. Engl. J. Med. – 2008. – Vol.359, №23. – P. 2442–2455.
53. Rajendra A. Economics of chronic hepatitis B and hepatitis C / A. Rajendra, J.B. Wong // J . Hepatol. – 2007. –Vol.47, №4. – P. 608–617.
54. Takkenberg B. Baseline HBsAg level predict HBsAg loss in chronic hepatitis B patients treated with a combination of peginterferon alfa-2a and adefovir: an interim analysi / B. Takkenberg, H. Zaaijer, C. Weegink et al. // J. Hepatol. – 2009. – Vol 50 (Suppl 1) . – P. S8.
55. Rizzetto M. Treatment of chronic delta hepatitis with alpha-2 recombinant interferon / M. Rizzetto, F. Rosina, G. Saracco et al. // J. Hepatol. – 1986. – Vol.3. – Suppl.2. – P. 229–233.
56. Rosina F. A randomized controlled trial of a 12-month course of recombinant human interferon-alpha in chronic delta (type D) hepatitis: a multicenter Italian study / F. Rosina, C. Pintus, C. Meschievitz et al. // Hepatology. – 1991. – Vol.13, №6. – P. 1052–1056.
57. Farci P. Treatment of chronic hepatitis D with interferon alfa-2a / P. Farci, A. Mandas, A. Coiana et al. //N.Engl.J.Med.– 1994. – Vol.330, №2. – P. 88–94.
58. Gaudin G.L. The French experience of treatment of chronic type D hepatitis with a 12-month course of interferon alpha-2B. Results of a randomized controlled trial / G.L. Gaudin, P. Faure, H. Godinot et al. // Liver – 1995. – Vol.15, №1. – P. 45–52.
59. Castelnau C. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up / C. Castelnau, F. Le Gal, M.P. Ripault et al. // J. Hepatol. – 2006. – Vol.44, №3. – P. 728–735.
60. Niro G.A. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta / G.A. Niro, A. Ciancio, G.B. Gaeta et al. //Hepatology. – 2006. – Vol.44, №3. – P. 713–720.
61. Heidrich B. Virological and clinical characteristics of delta hepatitis in Central Europe / B. Heidrich, K. Deterding, H.L.Tillmann et al. // J. Viral Hepat. – 2009. – № 12. – P. 883–94.
62. Yurdaydin C. Hepatitis D. / C. Yurdaydin, E.S. Koytak, J.S. Glenn // Curr Treat Options Gastroenterol. – 2007. – Vol.10, №6. – P. 456–463.
63. Балаян М.С. Вирусные гепатиты. Энциклопедический словарь. – 2-е изд. / М. С. Балаян, М. И. Михайлов. – М., 1999. – 42 с.
64. Weisberg I. New Treatments for Hepatitis C: Life Cycle Lessions / I. Weisberg, S.H. Sigal, I.M. Jacobson //Current Hepatitis Reports. – 2007. – Vol.6. – P. 75–82.
65. Marcellin P. Recombinant human gamma-interferon in patients with chronic active hepatitis B: pharmacokinetics, tolerance and biological effects / P. Marcellin, M.A. Loriot, N. Boyer et al. // Hepatology. – 1990. – Vol.12, №1. – P. 155–158.
66. Tripi S. Interferon-alpha alone versus Interferonalpha plus Ribavirin in Patients with Chronic Hepatitis C Not Responding to Previous Interferon-alpha Treatment / S. Tripi, G. Di Gaetano, M. Soresi et al. // BioDrugs. – 2000. – Vol.13, №4. – P. 299–304.
67. Barbaro G. Interferon-alpha-2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon-alpha alone: an Italian multicenter, randomized, controlled, clinical study / G. Barbaro, G. Di Lorenzo, M. Soldini et al. // Am J. Gastroenterol. – 1998. – Vol.93, №12. – P. 2445–2451.
68. Clarysse C. Genotype, serum level of HCV-RNA and response to interferon-alpha treatment in patients with chronic hepatitis C / C. Clarysse, C. Van den Eynde, F. Nevens et al. // Neth. J. Med. – 1995. – Vol.47, №6. – P. 265–271.
69. Lee S.S. Pilot study of interferon-alpha and ribavirin treatment in patients with chronic hepatitis C and normal transaminase values/ S.S. Lee, M. Sherman // J Viral Hepat. – 2001. – Vol. 8, №3. – Р. 202–205.
70. Saracco G. The long-term efficacy of interferon alfa in chronic hepatitis C patients: a critical review / G. Saracco, M. Rizzetto // J. Gastroenterol., Hepatol. – 1995. – Vol.10, №6. – P. 668–673.
71. Manns M.P. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial / M.P. Manns, J.G. McHutchison, S.C. Gordon et al. // Lancet. – 2001. – Vol.358, №9286. – P. 958–965.
72. Hadziyannis S.J. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose; PEGASYS International Study Group / S.J. Hadziyannis, H. Jr. Sette, T.R. Morgan et al. // Ann Intern Med. – 2004. – Vol.140, №5. – P. 346–355.
73. Лобзин Ю.В. Вирусные гепатиты: клиника, диагностика, лечение / Ю.В. Лобзин, К.В. Жданов, В.М. Волжанин, Д.А. Гусев. – Санкт-Петербург: Фолиант. – 2006. – 184 с.
74. Marcellin P. Improved Prediction of SVR by Differentiating Early Virologic Response (EVR) into Rapid Virologic Response (RVR), Complete EVR (cEVR) and Partial EVR (pEVR) in Genotype 1 Patients Treated ith Peginterferon Alfa- 2a (40KD) Pegasys ) and Ribavirin (Copegus ) / P. Marcellin, D. Jensen, S. J. Hadziyannis et al. // Hepatology International. – Vol.2, Supplement 3, №3 – 2008. – Abstract FP022. – P. 332.
75. Jensen D.M. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy / D.M. Jensen, T.R. Morgan , P. Marcellin et al. // J. Hepatol. – 2006. – Vol.43, №5. – P. 954–60.
76. Zeuzem S. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia / S .Zeuzem, M. Buti, P. Ferenci et al. // J. Hepatol. – 2006. – Vol.44, №1. – P. 97–103.
77. Fried M.W. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection / M.W. Fried, M.L. hiffman, K.R. Reddy et al. // N. Engl. J. Med.– 2002. – Vol.347, №13. – P. 975–982.
78. Ferenci P. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin / P. Ferenci, M.W. Fried, M.L. Shiffman et al. // J. Hepatol. – 2005. – Vol.43, №3. – P. 425–433.
79. Berg T. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferonalfa-2a plus ribavirin / T. Berg, M. von Wagner, S. Nasser et al. // J. Gastroenterol. – 2006. – Vol.130, №4. – P. 1086–1097.
80. Sanchez – Tapias J.M. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment / J.M. Sanchez – Tapias, M. Diago, P. Escartín, J. Enríquez et al. //J. Gastroenterol. – 2006. – Vol.130, №4. – 1086–1097.
81. Bronowicki J.P. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin / J.P. Bronowicki, D. Ouzan, T.Asselah et al. // J. Gastroenterol. – 2006. – Vol.131, №4. – P. 1040- 1048.
82. Pearlman B.L. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders / B.L. Pearlman, C. Ehleben, S. Saifee // J. Hepatol. – 2007. – Vol.46, №6. – 1688–1694.
83. Fried M.W., Rapid virological response is a more important predictor of sustained virological response (SVR) than genotype in patients with chronic hepatitis C virus infection / M.W. Fried // Program and abstracts of the 43rd Annual Meeting of the European Association for the Study of the Liver. – J. Hepatol. – April 2008.
84. Dalgard O. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response / O. Dalgard, K. Bjøro, H. Ring-Larsen et al. // J. Hepatol. – 2008. – Vol.47, №1. – P. 35–42.
85. Shiffman M.L. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3; ACCELERATE Investigators / M.L. Shiffman, F. Suter, B.R. Bacon et al. // N. Engl. J. Med. – 2007. – Vol.357, №2. – P. 124–134.
86. Willems B. 48 Weeks & High Ribavirin Dose May Improve SVR Rates for Genotype 2/3, French study / B. Willems // Program and abstracts of the 42nd Meeting of the EuropeanAssociation for the Study of Liver Diseases. – J. Hepatol. – April 2007.
87. Fried M.W. Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin / M.W. Fried, D.M. Jensen, M. Rodriguez-Torres et al. // J. Hepatol. – 2008. – Vol.48, №4. – P.1033–1043.
88. Safety and Efficacy of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1 (Study P05216AM1) (SPRINT-2). In print // www.clinicaltrials. gov/ct2/show/NCT00705432?term=SPRINT-2&rank=1.
89. Zeuzem S. Telaprevir in combination with peginterferon –alfa-2а with or without ribavirin in the treatment of chronic hepatitis C: final results of the prove2 / S. Zeuzem, C. Hezode, P. Ferenci et al. // Abstract 243. – J. Hepatol. – 2008. – Vol.48, №4 (suppl). – P. 113 A.
90. Gane E.G. Antiviral activity of the HCV nucleocide polymerase inhibitor R7128 in HCV genotype 2 and 3 prior nonresponders: interim results of R7128 1500 mg BID with PEG-IFN and ribavirin for 28 days / E.G. Gane, M. Rodriguez-Torres, D.R. Nelson et al. // J. Hepatol., Abstract LB10. – 2008. – Vol.48, №4 (suppl). – P. 267 A.
91. Maylin S. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C / S. Maylin, M. Martinot-Peignoux, R. Moucari et al. // J. Gastroenterol. – 2008. – Vol.135, №3. – P. 821–829.
Review
For citations:
Zhdanov K.V., Kozlov K.V., Sukachev V.S. Evolution of antiviral treatment chronic for hepatitis B, C and D. Journal Infectology. 2009;1(4):23-35. (In Russ.) https://doi.org/10.22625/2072-6732-2009-1-4-23-35
Views:
773
.png)
.png)
Email this article 